Mod GRF 1-29 (CJC-1295 no DAC)
Overview
Modified GRF 1-29 is a synthetic analogue of growth hormone releasing hormone (GHRH) comprising 29 amino acids with four amino acid substitutions to enhance stability. These modifications increase resistance to enzymatic degradation compared to native GHRH while maintaining receptor affinity and biological activity. The compound stimulates pulsatile growth hormone release from the anterior pituitary without the half-life extension conferred by drug affinity complex technology.
Key Research Findings
Preclinical studies have demonstrated enhanced growth hormone secretion and improved pharmacokinetic stability relative to native GHRH. No formal clinical trials have been published in peer-reviewed literature, and the compound lacks regulatory evaluation by major health authorities. Its use has been primarily documented in performance enhancement contexts outside approved therapeutic settings.
Subcutaneous injection
Research Phase
Interested in Mod GRF 1-29 (CJC-1295 no DAC)?
Find a verified provider experienced with Mod GRF 1-29 (CJC-1295 no DAC) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Mod GRF 1-29 (CJC-1295 no DAC) ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.